{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=53", "query": { "intervention": "docetaxel", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 1321, "total_pages": 133, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=54&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=52&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T13:38:15.563Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00327288", "title": "Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Breast Cancer", "Prostate Cancer" ], "interventions": [ { "name": "imexon", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AmpliMed Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2005-10", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-10-31T13:38:15.563Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00327288" }, { "nct_id": "NCT04337580", "title": "Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Refractory Cancer", "Castration Resistant Prostatic Cancer" ], "interventions": [ { "name": "Omeprazole 80 mg twice daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2021-03-05", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-31T13:38:15.563Z", "location_count": 2, "location_summary": "Salisbury, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Salisbury", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04337580" }, { "nct_id": "NCT06940180", "title": "Toripalimab With Chemotherapy for Sinus Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sinonasal Cancer", "Paranasal Sinus Neoplasms", "Squamous Cell Carcinoma", "Sinonasal Undifferentiated Carcinoma", "Locally Advanced Head and Neck Cancer" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-06-17", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-31T13:38:15.563Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06940180" }, { "nct_id": "NCT05583188", "title": "Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "Aliya Pulsed Electric Fields (PEF) ablation", "type": "DEVICE" }, { "name": "Nivolumab plus Platinum Doublet Chemotherapy", "type": "DRUG" }, { "name": "Standard of care neoadjuvant therapy", "type": "DRUG" }, { "name": "Surgical Resection", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "DRUG", "OTHER" ], "sponsor": "Galvanize Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2023-02-01", "completion_date": "2024-03-18", "has_results": false, "last_update_posted_date": "2024-07-19", "last_synced_at": "2026-10-31T13:38:15.563Z", "location_count": 3, "location_summary": "Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05583188" }, { "nct_id": "NCT00090610", "title": "Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 150, "start_date": "2003-10", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2015-02-25", "last_synced_at": "2026-10-31T13:38:15.563Z", "location_count": 19, "location_summary": "Fort Myers, Florida • Jupiter, Florida • Orlando, Florida + 16 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Bettendorf", "state": "Iowa" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00090610" }, { "nct_id": "NCT04592913", "title": "Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastrointestinal Neoplasms", "Esophagogastric Junction" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "FLOT chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "200 Years", "sex": "ALL", "summary": "18 Years to 200 Years" }, "enrollment_count": 957, "start_date": "2020-11-17", "completion_date": "2027-09-27", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-31T13:38:15.563Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Sylmar, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592913" }, { "nct_id": "NCT00186420", "title": "Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Taxotere", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 13, "start_date": "2003-07", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2012-06-13", "last_synced_at": "2026-10-31T13:38:15.563Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00186420" }, { "nct_id": "NCT00002662", "title": "Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aventis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "1994-08", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-10-31T13:38:15.563Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002662" }, { "nct_id": "NCT01485861", "title": "Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Apitolisib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 298, "start_date": "2012-01-11", "completion_date": "2022-08-31", "has_results": true, "last_update_posted_date": "2023-09-14", "last_synced_at": "2026-10-31T13:38:15.563Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • San Francisco, California • Fort Myers, Florida + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485861" }, { "nct_id": "NCT01966471", "title": "A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab Emtansine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1846, "start_date": "2014-01-31", "completion_date": "2021-06-04", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-31T13:38:15.563Z", "location_count": 50, "location_summary": "Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01966471" } ] }